Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gugliotta

Showing results (411-420 of 469) with videos related to

Pageof 47
Sort By:
Oncotarget|May 24, 2017
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cellsSimona Salati, Valentina Salvestrini, Chiara Carretta, et al.
Annals of Hematology|October 4, 2011
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre studyEsther Natalie Oliva, Andrea Piccin, Maria Gabriella Mazzucconi, et al.
Haematologica|March 23, 2010
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseFrancesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, et al.
The Oncologist|October 18, 2014
Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based methodAnna Sapino, Francesca Maletta, Ludovica Verdun di Cantogno, et al.
Leukemia|June 20, 2020
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML surveyMassimo Breccia, Elisabetta Abruzzese, Monica Bocchia, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.
Annals of Hematology|April 20, 2023
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trialsLuigia Luciano, Roberto Latagliata, Gabriele Gugliotta, et al.
Annals of Hematology|December 25, 2009
High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized studyCarlo L Balduini, Luigi Gugliotta, Mario Luppi, et al.
American Journal of Hematology|January 7, 2010
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemiaValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Pageof 47

Showing results (411-420 of 469) with videos related to

Sort By:
Pageof 47
Oncotarget|May 24, 2017
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cellsSimona Salati, Valentina Salvestrini, Chiara Carretta, et al.
Annals of Hematology|October 4, 2011
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre studyEsther Natalie Oliva, Andrea Piccin, Maria Gabriella Mazzucconi, et al.
Haematologica|March 23, 2010
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseFrancesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, et al.
The Oncologist|October 18, 2014
Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based methodAnna Sapino, Francesca Maletta, Ludovica Verdun di Cantogno, et al.
Leukemia|June 20, 2020
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML surveyMassimo Breccia, Elisabetta Abruzzese, Monica Bocchia, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.
Annals of Hematology|April 20, 2023
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trialsLuigia Luciano, Roberto Latagliata, Gabriele Gugliotta, et al.
Annals of Hematology|December 25, 2009
High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized studyCarlo L Balduini, Luigi Gugliotta, Mario Luppi, et al.
American Journal of Hematology|January 7, 2010
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemiaValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Pageof 47